Adam Patterson
Adam Patterson
Verified email at
Cited by
Cited by
Targeting gene expression to hypoxic tumor cells
GU Dachs, AV PATTERsoN, JD Firth, PJ Ratcliffe, KMS Townsend, ...
Nature medicine 3 (5), 515-520, 1997
Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix
R Airley, J Loncaster, S Davidson, M Bromley, S Roberts, A Patterson, ...
Clinical cancer research 7 (4), 928-934, 2001
Mapping of brain activity by automated volume analysis of immediate early genes
N Renier, EL Adams, C Kirst, Z Wu, R Azevedo, J Kohl, AE Autry, L Kadiri, ...
Cell 165 (7), 1789-1802, 2016
Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104
AV Patterson, DM Ferry, SJ Edmunds, Y Gu, RS Singleton, K Patel, ...
Clinical Cancer Research 13 (13), 3922-3932, 2007
Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302
F Meng, JW Evans, D Bhupathi, M Banica, L Lan, G Lorente, JX Duan, ...
Molecular cancer therapeutics 11 (3), 740-751, 2012
Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase
AV Patterson, H Zhang, A Moghaddam, R Bicknell, DC Talbot, IJ Stratford, ...
British journal of cancer 72 (3), 669-675, 1995
Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia
CP Guise, AM Mowday, A Ashoorzadeh, R Yuan, WH Lin, DH Wu, ...
Chinese journal of cancer 33 (2), 80, 2014
The views and practice of oncologists towards nutritional support in patients receiving chemotherapy
A Spiro, C Baldwin, A Patterson, J Thomas, HJN Andreyev
British journal of cancer 95 (4), 431-434, 2006
The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3
CP Guise, MR Abbattista, RS Singleton, SD Holford, J Connolly, ...
Cancer research 70 (4), 1573-1584, 2010
Structure− activity relationships of 1, 2, 4-benzotriazine 1, 4-dioxides as hypoxia-selective analogues of tirapazamine
MP Hay, SA Gamage, MS Kovacs, FB Pruijn, RF Anderson, AV Patterson, ...
Journal of medicinal chemistry 46 (1), 169-182, 2003
A critical evaluation of the relationship between serum vitamin B12, folate and total homocysteine with cognitive impairment in the elderly
M Ellinson, J Thomas, A Patterson
Journal of human nutrition and dietetics 17 (4), 371-383, 2004
Novel chimeric gene promoters responsive to hypoxia and ionizing radiation
O Greco, B Marples, GU Dachs, KJ Williams, AV Patterson, SD Scott
Gene therapy 9 (20), 1403-1411, 2002
Enzymology of tirapazamine metabolism: a review
AV Patterson, MP Saunders, EC Chinje, LH Patterson, IJ Stratford
Anti-cancer drug design 13 (6), 541-573, 1998
Bystander or no bystander for gene directed enzyme prodrug therapy
GU Dachs, MA Hunt, S Syddall, DC Singleton, AV Patterson
Molecules 14 (11), 4517-4545, 2009
Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954
GA Prosser, JN Copp, SP Syddall, EM Williams, JB Smaill, WR Wilson, ...
Biochemical pharmacology 79 (5), 678-687, 2010
Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233)
AV Patterson, HM Barham, EC Chinje, GE Adams, AL Harris, IJ Stratford
British journal of cancer 72 (5), 1144-1150, 1995
Overexpression of human NADPH: cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069
AV Patterson, MP Saunders, EC Chinje, DC Talbot, AL Harris, IJ Strafford
British Journal of Cancer 76 (10), 1338-1347, 1997
Cancer chemotherapy and drug metabolism
DS Riddick, C Lee, S Ramji, EC Chinje, RL Cowen, KJ Williams, ...
Drug Metabolism and Disposition 33 (8), 1083-1096, 2005
2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT
NA Helsby, DM Ferry, AV Patterson, SM Pullen, WR Wilson
British journal of cancer 90 (5), 1084-1092, 2004
Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH: cytochrome P450 oxidoreductase under hypoxia
CP Guise, AT Wang, A Theil, DJ Bridewell, WR Wilson, AV Patterson
Biochemical pharmacology 74 (6), 810-820, 2007
The system can't perform the operation now. Try again later.
Articles 1–20